DOP2016000152A - Quinazolin-thf-aminas como inhibidores de pde1. - Google Patents

Quinazolin-thf-aminas como inhibidores de pde1.

Info

Publication number
DOP2016000152A
DOP2016000152A DO2016000152A DO2016000152A DOP2016000152A DO P2016000152 A DOP2016000152 A DO P2016000152A DO 2016000152 A DO2016000152 A DO 2016000152A DO 2016000152 A DO2016000152 A DO 2016000152A DO P2016000152 A DOP2016000152 A DO P2016000152A
Authority
DO
Dominican Republic
Prior art keywords
aminas
quinazolin
thf
pde1 inhibitors
pde1
Prior art date
Application number
DO2016000152A
Other languages
English (en)
Inventor
Jan Kehler
Lars Kyhn Rasmussen
Morten Langgård
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of DOP2016000152A publication Critical patent/DOP2016000152A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA QUINAZOLIN-THF-AMINAS COMO INHIBIDORES DE PDE1 Y SU USO COMO UN MEDICAMENTO, EN PARTICULAR PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS Y TRASTORNOS PSIQUIÁTRICOS.
DO2016000152A 2013-12-19 2016-06-17 Quinazolin-thf-aminas como inhibidores de pde1. DOP2016000152A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201300707 2013-12-19
DKPA201400249 2014-05-06

Publications (1)

Publication Number Publication Date
DOP2016000152A true DOP2016000152A (es) 2016-09-30

Family

ID=52350066

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000152A DOP2016000152A (es) 2013-12-19 2016-06-17 Quinazolin-thf-aminas como inhibidores de pde1.

Country Status (26)

Country Link
US (3) US9701665B2 (es)
EP (1) EP3083607B1 (es)
JP (1) JP6419832B2 (es)
KR (1) KR20160098269A (es)
CN (1) CN105829300B (es)
AP (1) AP2016009293A0 (es)
AU (1) AU2014368601B2 (es)
BR (1) BR112016013946A8 (es)
CA (1) CA2933299A1 (es)
CL (1) CL2016001488A1 (es)
CR (1) CR20160282A (es)
DO (1) DOP2016000152A (es)
EA (1) EA201691108A1 (es)
EC (1) ECSP16061208A (es)
ES (1) ES2728079T3 (es)
GE (1) GEP201706764B (es)
IL (1) IL246230A0 (es)
MX (1) MX2016007945A (es)
PE (1) PE20160855A1 (es)
PH (1) PH12016501173A1 (es)
RU (1) RU2016125315A (es)
SG (1) SG11201604936TA (es)
SV (1) SV2016005220A (es)
TN (1) TN2016000239A1 (es)
TW (1) TW201609713A (es)
WO (1) WO2015091805A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609713A (zh) 2013-12-19 2016-03-16 H 朗德貝克公司 作爲pde1抑制劑之喹唑啉-thf-胺
AU2015239696B2 (en) 2014-04-04 2019-10-24 H. Lundbeck A/S Halogenated quinazolin-THF-amines as PDE1 inhibitors
TWI729109B (zh) * 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
EP3562828A1 (en) 2016-12-28 2019-11-06 Dart NeuroScience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
ES2902365T3 (es) 2017-11-27 2022-03-28 Dart Neuroscience Llc Compuestos de furanopirimidina sustituidos como inhibidores de PDE1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160307A0 (en) * 2001-08-31 2004-07-25 Univ Rockefeller Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
ZA200507228B (en) * 2003-04-01 2007-03-28 Applied Research Systems Inhibitors of phosphodiesterases in infertility
WO2005105803A2 (en) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
WO2007022280A1 (en) * 2005-08-16 2007-02-22 Memory Pharmaceuticals Corporation Phosphodiesterase 10 inhibitors
CA2641670A1 (en) 2006-02-23 2007-08-30 Pfizer Products Inc. Substituted quinazolines as pde10 inhibitors
CA2723372A1 (en) * 2008-05-05 2009-11-12 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
WO2010132127A1 (en) * 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
EP2480537A1 (en) * 2009-09-24 2012-08-01 Basf Se Aminoquinazoline compounds for combating invertebrate pests
TW201609713A (zh) 2013-12-19 2016-03-16 H 朗德貝克公司 作爲pde1抑制劑之喹唑啉-thf-胺

Also Published As

Publication number Publication date
WO2015091805A1 (en) 2015-06-25
CN105829300B (zh) 2019-03-15
PE20160855A1 (es) 2016-09-23
MX2016007945A (es) 2016-10-12
SG11201604936TA (en) 2016-07-28
US10030007B2 (en) 2018-07-24
AU2014368601A1 (en) 2016-06-30
JP2017500339A (ja) 2017-01-05
ES2728079T3 (es) 2019-10-22
US20160318910A1 (en) 2016-11-03
US20170267664A1 (en) 2017-09-21
TN2016000239A1 (en) 2017-10-06
CN105829300A (zh) 2016-08-03
EP3083607B1 (en) 2019-04-24
GEP201706764B (en) 2017-10-25
CR20160282A (es) 2016-09-06
CA2933299A1 (en) 2015-06-25
JP6419832B2 (ja) 2018-11-07
IL246230A0 (en) 2016-08-02
KR20160098269A (ko) 2016-08-18
ECSP16061208A (es) 2017-08-31
US20150175584A1 (en) 2015-06-25
EA201691108A1 (ru) 2016-09-30
EP3083607A1 (en) 2016-10-26
US9701665B2 (en) 2017-07-11
PH12016501173A1 (en) 2016-08-15
BR112016013946A8 (pt) 2018-01-30
TW201609713A (zh) 2016-03-16
AP2016009293A0 (en) 2016-06-30
CL2016001488A1 (es) 2016-12-09
BR112016013946A2 (pt) 2017-08-08
AU2014368601B2 (en) 2018-07-05
RU2016125315A (ru) 2018-01-24
SV2016005220A (es) 2016-11-30

Similar Documents

Publication Publication Date Title
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
ECSP18093944A (es) 1H-Pirazolo[4,3-b]piridinas como inhibidores de PDE1
DOP2016000152A (es) Quinazolin-thf-aminas como inhibidores de pde1.
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1